Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-line treatment

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qilu Hospital of Shandong University
• Collaborator: Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Antibodies; Poly(ADP-ribose) Polymerase Inhibitors

Criteria

Inclusion Criteria:

1. All subjects were required to sign the informed consent before starting the study;

2. Histologically documented Extensive stage small cell lung cancer；

3. ECOG PS 0~1 ；

4. 18-75 years；

5. According to recist1.1, CR or PR was achieved after 4-6 cycles of first-line etoposide and platinum chemotherapy;

6. .Life expectancy ≥ 3 months；

Exclusion Criteria:

1. Recurrence or distant metastasis of localized small cell lung cancer after chemotherapy or concurrent chemoradiotherapy；

2. Active infection including tuberculosis, HIV, hepatitis B and C；

3. Interstitial pneumonia (ILD), drug-induced pneumonia, radiation-induced pneumonia requiring steroid therapy or active pneumonia with clinical symptoms, or other moderate to severe lung diseases that seriously affect lung function;

4. Severe infection existed, including but not limited to infection complications, bacteremia, severe pneumonia, etc;

5. Symptomatic brain metastasis and cancerous meningitis;